Conference Coverage

Pemphigus remission rate tops 80% with rituximab

 

Key clinical point: Rituximab puts the majority of pemphigus patients in remission, with a median time between doses of about 2 years.

Major finding: Sixty-one percent of patients achieved complete healing of their skin after one cycle, increasing to 82% when those who had more than one cycle were included.

Study details: A single-center review of 113 patients

Disclosures: There was no industry funding, and the lead investigator had no disclosures.

Source: Kushner CJ et al. IID 2018, Abstract 552.


 

REPORTING FROM IID 2018

Rituximab (Rituxan) is under priority review by the Food and Drug Administration for pemphigus vulgaris, and could be approved for the indication soon.

With approval pending, “rituximab is quickly emerging as frontline therapy” for pemphigus, so “we should begin to prepare to answer our patients’ questions. It’s likely they will be interested in its use,” said Carolyn Kushner, a medical student and dermatology research fellow at the University of Pennsylvania, Philadelphia. Rituximab manufacturer Genentech announced the priority review for this indication in a Feb. 2018 press release.

Carolyn Kushner University of Pennsylvania, Philadelphia M. Alexander Otto/MDedge News

Carolyn Kushner

Ms. Kushner presented a review of off-label rituximab outcomes in 113 patients treated at the university’s hospital between 2004 and 2017, 97 with pemphigus vulgaris and 16 with pemphigus foliaceus. All were followed for at least a year, and some for over 10 years. It’s likely the largest single-center review of rituximab for pemphigus.

“We get a lot of questions in the clinic,” she said at the International Investigative Dermatology meeting. Patients with pemphigus want to know how well rituximab will work, and if they’ll be able to go off other medications. They wonder if it’s safe, and when they’ll need to be retreated. The goal of the study was to provide information for both clinicians and patients regarding what to expect from the treatment.

Overall, 54 patients (48%) achieved a complete response off therapy (CROT) after their first treatment cycle, meaning they had no new lesions for at least 2 months off of all systemic and topical treatments. The median time to a complete response was 7.4 months, and the median time to relapse was 20.9 months after the first infusion. An additional 15 patients (13%) had a complete remission with minimal therapy after one cycle.


In short, “61% of patients achieved complete healing of their skin after one cycle,” Ms. Kushner said. The number rose to 82% (93 patients) when those who had more than one cycle were included. The maximum in the study was seven. Among all patients, the median time from the first to second rituximab dose was 25.1 months.

When age, sex, and disease duration were controlled for, patients who received lymphoma dosing – 375 mg/m2 weekly for 4 weeks – were 2.7 times more likely to achieve CROT than those on the rheumatoid arthritis dosing, two 1,000 mg IV infusions 2 weeks apart (P = .037). “We almost never use RA dosing now,” she said.

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge